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a  b  s  t  r  a  c  t
Aim: To review the recent evolution of spine SBRT with emphasis on single dose treatments.
Background: Radiation treatment of spine metastases represents a challenging problem in
clinical oncology, because of the high risk of inflicting damage to the spinal cord. While con-
ventional fractionated radiation therapy still constitutes the most commonly used modality
for palliative treatment, notwithstanding its efficacy in terms of palliation of pain, local
tumor control has been approximately 60%. This limited effectiveness is due to previous
lack of technology to precisely target the tumor while avoiding the radiosensitive spinal
cord,  which constitutes a dose-limiting barrier to tumor cure.
Materials and methods: A thorough review of the available literature on spine SBRT has been
carried out and critically assessed.
Results: Stereotactic body radiotherapy (SBRT) emerges as an alternative, non-invasive
high-precision approach, which allows escalation of tumor dose, while effectively sparing
adjacent uninvolved organs at risk. Engaging technological advances, such as on-line Cone
Beam  Computed Tomography (CBCT), coupled with Dynamic Multi-Leaf Collimation (DMLC)
and  rapid intensity-modulated (IMRT) beam delivery, have promoted an interactive image-
guided (IGRT) approach that precisely conforms treatment onto a defined target volume with
a  rapid dose fall-off to collateral non-target tissues, such as the spinal cord. Recent techno-
logical developments allow the use of the high-dose per fraction mode of hypofractionated
SBRT for spinal oligometastatic cancer, even if only a few millimeters away from the tumor.Conclusion: Single-dose spine SBRT, now increasingly implemented, yields unprecedented
outcomes of local tumor ablation and safety, provided that advanced technology is
employed.
land 
breast, lung, prostate, and renal cell carcinomas. It has been©  2015 Greater Po
1.  BackgroundSkeletal metastases are a common complication of cancer
which occurs in up to 40% of oncological patients.1 Disease
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histology most often metastatic to the spine includes theestimated that approximately 10% of cancer patients will
develop spine metastases and their management represents
one of the more  vexing clinical problems in clinical oncology.




























































reports of practical oncology and 
reatment options include pain management with narcotics,
teroids, radiation therapy, surgery, or combinations of the
bove. Surgery is usually indicated in patients who present
ith a good performance status and acute neurological
mpairment, requiring decompression and stabilization of
he spine. For unfit patients, or those with a mechanically
table spinal metastasis with or without malignant cord
ompression, conventional fractionated radiation therapy
as been, so far, the mainstay of the palliative management.
lthough the issue of dose–pain response has not been fully
stablished yet, several prospective studies indicate that a
ingle dose of 8–10 Gy is equivalent to the classically used
egimen of fractionated 30 Gy in 10 fractions.2–5 However,
ong-term control of symptoms, even for favorable histologies
s, at best, approximately 60%, with a median duration of
alliation of approximately 4 months.6,7
The limited effectiveness of fractionated radiotherapy is
nherent to the technological restrictions of this approach.
 fundamental issue is the uncertainties in targeting deep-
eated tumors, conventionally guided by skin markings
stablished during the simulation procedure. Small daily vari-
tions in the location of the skin markings relative to the
arget mandates the use of expanded safety margins around
he tumor to avoid geographical tumor miss. Such safety
argins frequently capture significant portions of the spinal
ord, which restricts the treatment dose to levels lower than
equired for tumor ablation.8,9 The technological revolution of
mage-guided treatment delivery systems, entailing new abil-
ties to visualize the tumor during treatment with on-board
maging and to employ computer-driven technology to re-
djust tumor targeting on-line have promoted new standards
f tumor ablation with ionizing radiation. It is now possible
o achieve an extreme precision of target coverage with tumo-
icidal dose levels, while sparing the cord even if only a few
illimeters away from the tumor. The ability to “visually”
issect the tumor from adjacent normal tissues with radia-
ion beams has promoted and accelerated the implementation
f new applications to ablate human tumors, such as with
ypofractionated SBRT.
The use of this approach has expanded in the past
ecade to the management of patients with oligometastatic
resentations (defined as initial 1–5 synchronous lesions),
hich appear to have a potential for long-term survival
f the metastatic lesions are therapeutically controlled.
ligometastatic disease has been postulated to represent a
iologically distinct phenotype with limited spread, consti-
uting an intermediate phase in the pathway of metastatic
ransformation preceding the acquisition of a potential
or widespread dissemination by metastatogenic tumor
lonogens.10–11 Large surgical series have shown long-term
isease-free survival of ≥20% at 10–20 years following resec-
ion of oligometastatic deposits in the liver or lung, and
everal prospective clinical studies, currently underway, have
een designed to test the curative potential of high-dose SBRT
nstead of surgery.12 The strict criteria employed to ablate
ligometastatic tumor deposits by SBRT accommodate the
pecial needs of local tumor control in the spine, critical for
revention of cord compression by tumor extension into the
pidural space. The purpose of this review is to summarize
he growing body of literature on spine SBRT with specifictherapy 2 0 ( 2 0 1 5 ) 454–463 455
emphasis on the emerging new approach with single dose
IGRT, an SBRT application that has attracted a great deal of
attention because of its unique contribution to the quality of
care in this clinical setting.
2.  Technical  and  dosimetric  considerations
in  spine  SBRT
SBRT was developed in the mid-1990s using concepts that
had been already established in the treatment of intracranial
lesions with stereotactic radiosurgery (SRS). The first descrip-
tion of a linear-accelerator-based spinal SBRT was published
in 1995 by Hamilton et al.13 Transition to linear accelerators
has been critical, as it enabled the use of treatment delivery
tools not available on SRS units to conform to complex tar-
get shapes and organ mobility. Indeed, the implementation
of new beam shaping and image  guidance technologies have
rapidly enhanced the sophistication and efficacy of SBRT in
reducing safety margins while precisely conforming to the
three-dimensional tumor outline. On-line Cone Beam Com-
puted Tomography (CBCT), Dynamic Multi-Leaf Collimation
(DMLC), rapid intensity-modulated (IMRT) beam delivery with
flattening Filter-Free (FFF) beams and on-line tracking tools
have promoted new standards of local tumor cure with on-line
image guided radiotherapy (IGRT).
A critical element in implementing SBRT for spine tumors
has been the progressive accumulation of data on dose-
volume radiation tolerance of the spinal cord. Data from
conventional fractionation regimens (1.8–2.0 Gy per fraction)
indicate that spinal cord tolerance may be higher than previ-
ously appreciated, with a risk of myelopathy of <1% at 54 Gy
and of 10% at 61 Gy.14 However, an exponential increase in the
risk of cord damage occurs as the dose per fraction increases
and the number of fractions is reduced, such as practiced
in the delivery of high dose SBRT. Information regarding the
dose tolerance of the spinal cord to high-dose radiation frac-
tions is beginning to emerge. Macbeth et al., analyzing data
from three randomized trials of palliative radiotherapy for
non-small cell lung cancer, reported 0% (0/114) risk of collat-
eral radiation-induced myelitis when the dose to the spine
was 10 Gy in a single fraction.15 While the estimated cumu-
lative risk of myelopathy at 2 years was 2.2% in 524 patients
treated with 17 Gy in two fractions. Other studies have sug-
gested that the spinal cord can tolerate at least a single dose
of 10 Gy to 10% of the cord segment that is adjacent to a
targeted tumor plus 6 mm above and below this segment,
with a risk of radiation-induced myelopathy of <0.5%.16 Sah-
gal et al. reported Dose-Volume Histograms (DVH) of nine
patients who developed radiation myelopathy post-SBRT and
compared them with a cohort of 66 spine SBRT patients who
did not develop the toxicity.17 A logistic regression model was
developed to establish the probability of myelopathy using the
thecal sac point maximum (Pmax) volume. A risk of ≤5% was
observed when limiting the thecal sac Pmax volume dose to
12.4 Gy in a single fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3
fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions.
Despite a reasonably accurate spatial precision in tumor
targeting with the use of modern technology, minute devi-
ations during spine SBRT may translate into significant
d rad456  reports of practical oncology an
dosimetric perturbations during spine SBRT because of
extremely steep dose gradients in the context of a close prox-
imity between the target and the spinal cord. The advent
of automated robotic couches with six degrees of freedom
(6DoF) enables rapid on-line target repositioning following
CBCT, improving the accuracy target coverage and spinal cord
avoidance. An analysis of set-up inaccuracies during spine
irradiation has documented translational errors of up to 1 mm
with a vector of 1.8 ± 1.0 mm and rotational errors of up to
1.6 ± 1.3◦ which may yield up to 18% errors in D(95).18 Clearly,
the accurate detection and appropriate correction of such
inconsistencies are of utmost importance for the safety of the
treatment.
3.  Rationale  of  single  dose  versus
hypofractionated  regimens
Numerous published series of spine SBRT have used a variety
of schedules, but a clear-cut definition of the optimal num-
ber of sessions, fraction size and total dose are still lacking.
A recent pooled analysis of published series using both single
fraction at various dose levels and multi-fraction regimens (up
to 5 sessions) entailed 1775 lesions in 1388 patients.19 Follow-
up was mostly short-termed (<18 months in 12/15 studies)
yielding an overall local control rate of 90% and a risk of radi-
ation myelopathy of 0.4%, with no apparent differences in
early outcomes between single dose and 3–5 fraction of SBRT.
Prospective randomized trials are few and largely still under-
way. The RTOG 0631 prospective phase III trial compares 8 Gy
with 16 Gy in single fractions to establish dose level effect on
pain.20 A prospective randomized phase III trial at Memorial
Sloan Kettering Cancer Center (MSKCC) in New York compares
24 Gy in a single fraction versus 3 sessions of 9 Gy (total 27 Gy)
in effecting durable local control in oligometastatic tumors,
including oligometastatic spine disease (MSKCC 10–154). This
study targets 200 patients, and spine lesions are eligible if the
cord is >3 mm away from the edge of the planned target vol-
ume  (PTV). The spinal cord constraint is defined as a point
Dmax of 15 Gy to the organ based on MRI  segmentation.
While prospective studies comparing the most effective
single dose versus hypofractionated SBRT options are not
available, retrospective analyses have provided an insight into
this issue. An apparent advantage for ultra-high single dose
SBRT was recently reported by Folkert et al. in patients treated
for spine and para-spinal metastatic sarcoma.21 Soft tissue
and bone sarcomas are notoriously radio-resistant by classical
radiobiological ranking, and conventional radiation treatment
(20–40 Gy at 2–5 Gy per fraction) is sub-curative, resulting in
low rates of local control. In this series, 88 patients with 120
discrete metastases received hypofractionation (3–6 fractions;
median dose, 28.5 Gy) or single fraction (median dose, 24 Gy).
With a median follow-up time of 12.3 months, the one-year
local control rate for the whole group was 87.9%, with single
dose patients showing superior local control of 90.8% versus
84.1% for hypofractionation (p = .007). It should be noted that
the single dose levels (median 24 Gy, range 18–24 Gy) were at
the high end of therapeutically feasible range, while the frac-
tionated dose levels (median 28.5 Gy, range 24–36 Gy) were at
the intermediate, arguably less effective, range.iotherapy 2 0 ( 2 0 1 5 ) 454–463
The issue of dose level is central to the evaluation of
SBRT outcome. A dose escalation study of single dose SBRT
for oligometastatic lesions in non-spinal locations has been
reported from MSKCC.22 At all dose levels >90% of relapses
occurred within 24 months post-treatment. A steep curve of
actuarial local control at ≥36 months by treatment dose was
observed, with 25% local cures at the dose range of 18–20 Gy,
69% at 21–22 Gy, and 88% in tumors receiving the 23–24 Gy
range (p < 0.05). Yamada et al. from MSKCC showed excellent
response rates at high doses in patients treated exclusively to
the spine, reporting a 95% actuarial local control at 3 years for
67 lesions treated with 24 Gy, compared to 80% in 36 lesions
treated with 18–23 Gy.23 The high rate of local control with
ultra-high single doses was validated in an independent series
at the Champalimaud Centre of the Unknown (CCU) in Lisbon,
observing a 94% 2-year actuarial control in 235 oligometastatic
lesions receiving 24 Gy SBRT. Interestingly, all of the above
studies showed that at high dose, all tumor types, whether
sensitive or resistant to classical fractionated radiotherapy,
responded with ∼90% local cure, a phenomenon that chal-
lenges classical tenets of clinical radiobiology.
Similar patterns of local cure were, however, observed with
hypofractionated SBRT schemes when high dose per fraction
was used. McCammon et al. reported a 3-year actuarial local
control rate of 89.3% in 105 primary or metastatic lesions to
the lung and liver treated with 3 fractions of 18–20 Gy, com-
pared with 59.0% in 59 lesions treated with 3 fractions of
14–16 Gy and 8.1% in 82 lesions exposed to ≤12 Gy per fraction
in 3 sessions.24 However, while hypofractionation does pro-
vide equivalent local control to single-dose SBRT, a high dose
per fraction, exceeding 18 Gy, is required. In this context, it
should be noted that the AAPM guidelines for SBRT dose con-
straints for critical normal organs has identified 14–15 Gy as an
approximate common threshold for a maximal safe point dose
to the so-called serial normal tissues, which include the CNS
tissues.25 Hence, the delivery of 3 fractions of 16–20 Gy requires
the same elaborate and diligent IGRT-based treatment deliv-
ery at each fraction as for single-dose 24 Gy treatment, to avoid
normal tissue toxicity. Ultra-high single dose should, there-
fore, be regarded as more  cost-effective and potentially safer
than hypofractionated SBRT in achieving an iso-therapeutic
effect. It is for this reason that perspectives of single dose
SBRT have attracted much attention and experimental activ-
ity in the search for optimizing the treatment approach in
metastatic disease of the spine.
4.  Outcomes  of  single  dose  SBRT  for  spine
tumors
The two main therapeutic targets of single dose SBRT for spine
metastases, namely pain control and spine stabilization to
avoid cord compression, have each been explored in series of
phase I and II studies (Table 1), but outcome data of phase
III studies are not available as of yet. While a dose escala-
tion study for durable tumor control has established a dose
response relationship,23 a similar relationship for pain con-
trol has not been fully established. A study from the Henry
Ford Hospital in Detroit reported a trend for improved pain
relief with higher radiation doses.26 In this study, 61 spinal
reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 454–463 457
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esions in 49 patients were treated with escalating doses (2 Gy
ncrements) within the range of 10–16 Gy (6–20 lesions in each
ose bin), delivered to the involved spinal segment alone. Pain
elief was evaluated using a verbal/visual analog scale, with
ain intensity description ranging from zero (no pain) to 10
the worst imaginable pain). A univariate analysis failed to
how a significant decrease in pain score with dose, although
 strong trend in this direction was observed at doses ≥14 Gy.
verall, pain relief, when achieved, was rapid, and at 4 weeks
 complete pain relief was documented in 37.7%, partial relief
n 47.6%, and worsening of pain in 1.6%. The median duration
f pain relief was 13.6 months, and pain control was durable at
ne year in 84%. The 1-year survival in this group of patients
as 74.3%, and there was no evidence for neurological toxic-
ty.
The most extensive study of pain relief by single dose
BRT was reported by Gerszten et al.27 Metastatic tumors (500
esions in 393 patients) with multiple histologies were treated
ith single doses of 12–22.5 Gy, prescribed to 80% of isodose
urface (mean 20 Gy). Exclusion criteria were evidence of overt
pinal instability and/or neurological deficit resulting from
ony compression of neural structures. Maximum doses to the
pinal cord and cauda equina (spinal canal) were 1.3–13.1 Gy
mean 8.6 Gy) and 1.1–13.3 Gy (mean 9 Gy), respectively. Sixty-
ine percent of the lesions were re-irradiated to relieve painord, max 10 Gy
relapsing after previous conventional low dose radiotherapy.
Improvement of pain symptoms was defined as a benefit of at
least 3 points on the 10-point visual analog scale. At a median
follow-up of 21 months, (range, 3–53 months), sustained pain
relief was observed in 86%. There were no neurological toxic-
ities attributable to treatment. Long-term local control, using
CT criteria, was achieved in 88% of all treated lesions. The
likelihood of tumor control was affected by histology, with
the breast and lung being the most radio-responsive (100%
local control), while renal cell cancer and melanoma exhib-
ited 87% and 75% local control rates, respectively. Subgroups
of this cohort were also reported separately. Ninety-six percent
of 68 spinal lesions in 50 breast cancer patients experienced
pain relief (mean 5 points on the visual scale) at a median
follow-up of 16 months (range 6–48), with no apparent acute
or sub-acute neurological toxicity.28 Similarly, long-term pain
improvement and no acute or sub-acute neurological toxici-
ties were reported in 77 lung cancer patients.29 The majority of
tumors in this series were non-small cell cancers (79/87, 91%),
and 80% (70/87) received re-irradiation of lesions relapsing
after previous conventional low dose radiotherapy. Patients
with metastatic melanoma (36 lesions in 28 patients) also
entertained excellent pain relief (96%), with a mean improve-
ment of 7 points in a 10-point visual scale, and no recorded
neurological toxicities.30
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While the above studies combined demonstrate the effi-
cacy of pain relief by the low and intermediate range of
clinically feasible single dose SBRT, without risk of cord
damage, the issue of pain relief dependence on dose has,
nonetheless, not been resolved. The RTOG 0631 trial has been
designed to address this issue, exploring in a prospective ran-
domized phase III trial pain relief with single dose 8 Gy versus
16 Gy.20 An initial phase II study was designed to establish
a baseline technical uniformity in accurate and reproducible
delivery of 16 Gy single dose SBRT within the institutions
participating in this cooperative group study, with rigorous
quality control requirements. The phase II base-line study was
completed with 44 patients with 1–3 spine metastases with
a Numerical Rating Pain Scale (NRPS) score ≥5 accrued and
treated with 16 Gy. The designed targeting accuracy ≤2 mm,
target volume coverage of >90% of prescription dose, and
spinal cord dose constraints (10 Gy to ≤10% of the cord volume
from 5–6 mm above to 5–6 mm below the tumor, or abso-
lute spinal cord volume <0.35 cm3) and other normal tissue
dose constraints were achieved with high compliance. Eleven
patients had grade 1–2 adverse events; however the major-
ity of these were unrelated to treatment. One grade 3 cervical
pain was identified as an acute adverse event associated with
SBRT, but there were no other acute treatment-related toxic-
ities. The phase III arm of the study has now been activated
with an anticipated accrual of 240 patients.
While pain relief appears to be responsive to single dose
SBRT, contributing significantly to alleviation of one of the
more deleterious complications of cancer metastases to the
spine, there is increasing awareness of the need to achieve
durable local control, as improvements in systemic treat-
ment are leading to an ever growing proportion of metastatic
patients that live longer. There is a growing body of compelling
evidence that spine SBRT provides durable tumor control that
is far superior to that achievable with conventional radiation
therapy. Studies of this notion were pioneered by Yamada
et al.23 An early report on the treatment of 103 lesions in 93
patients included only radiotherapy-naive lesions that were
not subject to prior surgical treatment. Exclusion criteria
included high-grade epidural cord compression and mechani-
cal instability. Whenever an involvement of the vertebral body
was present, the CTV included the entire body. Planning tar-
get volume consisted of the CTV plus a 2 mm margin with
avoidance of the spinal cord. Dose was prescribed to the 100%
isodose line and ranged between 18 and 24 Gy (median 24 Gy).
A maximum point dose of 14 Gy was used as spinal cord con-
straint. Patients were assessed at 3–4 months intervals. At
15 months median follow-up an actuarial local control rate
of 90% was observed. Interestingly, patients who experienced
local failure had a median time to failure of only 9 months
from treatment time (range 5–13 months). Median overall sur-
vival was 15 months (range 6–36). On multivariate analysis, no
statistically significant differences in overall survival or local
control were found when stratifying the series by histology
of the primary disease. However, there was a significant dose
effect when comparing low dose (18–23 Gy) with high dose
(24 Gy), with actuarial local control rates of 80 and 95%, respec-
tively (p = 0.03). A recent and expanded update of this series,
which now includes 412 lesions in 362 patients, confirms >90%
3-year local control in all histologies, reaching levels of 98%iotherapy 2 0 ( 2 0 1 5 ) 454–463
in breast, GI, lung and prostate tumors.31 The 3-year cumu-
lative incidence of local recurrence in the 24 Gy group (333
lesions) is 2.4%, compared with 10.4% in the 16–23 Gy cohort
(80 lesions) (p < 0.001). The median time to recurrence has not
changed, with only 2/6 patients in the 24 Gy group recurring
at ≥2 years. At a median follow-up of 16 months (range 2–78),
91% of lesions treated with 24 Gy show a persistent local con-
trol, 212/362 (59%) patients are alive without local relapse and
the other 132 (36%) died without local relapse.
A more  limited phase I and II study was reported by Garg
et al.32 A total of 63 metastases in 61 patients were treated
to a peripheral dose of 16–24 Gy in a single fraction. Mean
follow-up was 19.7 months (range, 1.2–52.1 months; median
17.8 months). CTV was defined as the GTV plus contiguous
bone marrow space with no margin for PTV. Dose prescription
varied according to location (spinal versus para-spinal) and
histology (renal versus non-renal). In non-renal spinal metas-
tases, 18 Gy was prescribed to the GTV with a mean of 16 Gy
to the CTV; in renal vertebral lesions the doses were 24 and
18 Gy to the GTV and CTV, respectively. The spinal cord was not
to receive more  than 10 Gy to more  than 0.01 cm3, and max-
imum allowed dose to the spinal cord plus 2 mm was 12 Gy.
The 18-months actuarial local control in this cohort was 88%.
Interestingly, pain level at 6 months turned out to be predictive
of local control: patients with pain level ≥4 fared worse com-
pared to those with less pain (p = 0.01). Neurological function
preservation correlated with overall survival (p < 0.01). None
of the patients had neurological deterioration attributable to
progression at the treated site. There were, however, 2 patients
who experienced high-grade neurological toxicity (1 myelopa-
thy, 1 radiculopathy).
Taken together, this series of publications demonstrated
the safety and high efficacy of single dose SBRT in provid-
ing a durable local tumor control and prevention of direct or
indirect cord compression by tumor growth. The high end of
the dose range tested appears to be required to assure >90%
success, and 24 Gy has consistently yielded this rate of local
control even in classical radioresistant phenotypes, such as
melanoma and renal cell carcinoma. This is in stark contrast
with fractionated radiotherapy data, suggesting a different
mechanism of tumor stem cell kill. In a retrospective analy-
sis of 105 cases of metastatic renal cell carcinomas treated (59
spinal lesions) with either hypofractionated or high dose IGRT
(dose range 18–24 Gy), Zelefsky et al. confirmed a strong pre-
dictive value of high prescription dose.33 The overall 3-year
actuarial local progression-free survival for all lesions was
44%. The 3-year local control for high single-dose (24 Gy), low
single-dose (<24 Gy), and hypofractionation were 88%, 21%,
and 17%, respectively (high single dose versus low single dose,
p = 0.001).
The assessment of treatment response is typically based on
imaging and long-term follow-up. Early predictive indicators
on success of treatment are highly desired, since information
would provide an indication for adjuvant treatment in patients
with a high risk of local failure. A recent approach to address
this issue has been to measure the magnitude of change
in metabolic uptake of FDG (SUV) as detected by positron
emission measurements post-single fraction as predictive of
long-term freedom from relapse.34 The use of this biomarker
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mplementation of state-of-the-art high-precision IGRT tech-
iques. To date, 51 metastatic spine lesions have been treated
ith SD-IGRT with doses ranging between 16 and 24 Gy (mean,
0.5 Gy, median, 24 Gy). The most prevalent histologies were
SCLC (34%), prostate (19%), and breast (19%). Median follow-
p is 18 months (range, 3–31 months). All patients have been
reated with fast FFF beams and Volumetric Modulated Arc
herapy (VMAT) plans. The MRI-based maximum cord dose
onstraint is 15 Gy. All cases have been planned and assessed
ost-treatment by PET/CT. Previous data suggests that the
agnitude of change in metabolic uptake (SUV) post-single
raction is predictive of long-term freedom from relapse.34
Fig. 1 shows a planning PET/CT and 3- and 24-month
ollow-up scans of a breast cancer solitary metastasis in the
ertebral body at L5 (prescription dose 24 Gy) which achieved a
omplete metabolic response at 3 months post-treatment. All
atients, with no exception, treated with high dose SBRT for
etastatic disease at CCU were prospectively assessed with
ET/CT and SUV response scores, according to criteria of
esponse correlated with traditional PERCIST. A preliminary
nalysis of the metastatic cohort shows that a decline of >70%
SUV>70%) at 3 months post-treatment appears to be signifi-
antly associated with local tumor control, as observed at CCU
n other types of treated tumors. Among patients who demon-
trated an initial SUV>70%, 97% achieved sustained metabolic
ocal control compared with 60% who did not demonstrate
ig. 1 – (a) Baseline PET/CT. Solitary L5 metastasis from breast ca
SUVmax 17.5). (b) Dose distribution of VMAT plan. Prescription 
ost-single dose IGRT 24 Gy Follow-up PET/CT (SUVmax <1). (d) 2therapy 2 0 ( 2 0 1 5 ) 454–463 459
an initial SUV>70% (p = 0.01). Longer follow-up is needed to
confirm the SUV approach as an early biomarker of response.
5.  Risk  of  vertebral  fracture  following
high-dose  spinal  RT
Little data exists on the risk of vertebral fracture to the spine
following high-dose SRS to the spine. Rose et al. evaluated 62
consecutive patients at 71 sites.35 Patients had no prior sur-
gical or radiation treatment to the region of interest. Single
dose prescription varied from 18 to 24 Gy as part of a deliber-
ate dose escalation scheme. Fracture progression was noted
in 27 vertebrae (39%). The risk of fracture progression was not
associated with dose within this range. Multivariate logistic
regression analysis showed that CT appearance, lesion loca-
tion, and percent vertebral body involvement independently
predicted fracture progression. Lesions located between T10
and the sacrum were 4.6 times more  likely to fracture than
were lesions above T10 (95% CI, 1.1–19.7). Lytic lesions were
6.8 times more  likely to fracture than were sclerotic and mixed
lesions. As percent vertebral body involvement increased, so
did the odds of fracture. Lytic disease involving more than 40%
of the vertebral body and location at or below T10 confer a
high risk of fracture, the presence of which yields significantly
poorer clinical outcomes. This data may be used as a guide for
ncer with extensive involvement of the vertebral body
dose 24 Gy to the PTV. 10 MV beam. (c) 3-Months
-Year follow-up PET/CT assessment (SUVmax <1).
460  reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 454–463
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he indication of preventive vertebroplasty prior to spine SBRT
n selected cases.
.  High-dose  spinal  RT  in  the  adjuvant
etting
ross spinal instability may require open surgery for decom-
ressing and stabilizing the spine. Persistence of gross disease
ost-operatively may be addressed with adjuvant radiation
herapy with the aim of improving local tumor control. In an
arly report, Rock et al. evaluated the combination of open
urgical procedure followed with adjuvant radiosurgery in a
eries of 18 patients. Doses ranged between 6 and 16 Gy (mean,
1.4 Gy) prescribed to the 90% isodose line.36 This treatment
aradigm was associated with a significant chance of stabi-
izing or improving neurological function. In this series, 92%
f patients initially presenting with neurological symptoms
ither remained neurologically stable or improved. Local con-
rol was 94%. Overall, the technique was deemed well tolerated
nd associated with little to no morbidity. Moulding et al.
eviewed 21 patients who  had undergone “separation surgery”
or radioresistant histologies.37 The radiation treatment vol-
me  was delineated based on the pre-operative imaging
tudies rather than the postoperative residual disease. The
pinal cord and thecal sac contours were established using
yelogram/CT, which provides excellent anatomic detail even
n the presence of spinal implants. The GTV received 24 Gy
n 16 patients and 18–21 Gy in 5 patients. Overall local con-
rol was 81% with an estimated one-year failure of 9.5%.
ocal control was significantly better in the cohort receiv-
ng 24 Gy compared to patients receiving less than 24 Gy (94%
ersus 60%, respectively). Recently, Laufer et al. retrospec-
ively reviewed the outcomes of 186 patients suffering from
etastatic epidural spinal cord compression treated with
urgical decompression, instrumentation, and postoperative
GRT delivered as either single-dose of 24 Gy (40/186; 21.5%),
igh-dose hypofractionation in 3 fractions and a total dose of
4–30 Gy (37/186; 19.9%), or low-dose hypofractionation in 5
r 6 fractions and a total dose of 18–36 Gy (109/186; 58.6%).38
he overall local progression rate after radiation was 16% at 1
ear. The only factor significantly associated with local tumor
rogression was the post-operative radiation dose, with the
igh-dose hypofractionated regimen resulting in a 4% local
rogression rate after 1 year, compared with the significantly
igher 1-year local progression rate of 22% for the low-dose
ypofractionated approach. The 1-year local progression rate
or single-fraction was 9%. No other variable significantly
orrelated with progression-free survival, including radiation
ensitivity of tumor histology, grade of epidural cord compres-
ion, extent of surgical decompression.
Some of the drawbacks of invasive surgery lie in the risks
f surgical morbidity and the potential delays in receiving
djuvant irradiation. The use of less invasive, percutaneous,
urgical approaches combined with SBRT is an active area of
urrent investigation which relies on the excellent long-term
umor control provided by high dose postoperative high-dose
GRT, potentially obviating the need for extensive tumor resec-
ion in favor of a limited spinal cord decompression. Recently,
assicotte et al. reported on the role of minimal access spinetherapy 2 0 ( 2 0 1 5 ) 454–463 461
surgery (MASS) in a small series as an adjunct to definitive
SBRT with a median time between surgery and irradiation
of only 7 days.39 The median total radiation dose was 24 Gy
(range, 18–35 Gy), in a mean of 3 fractions (range, 1–5). With
a median follow-up for the cohort of 13 months (range, 3–18),
local control based on imaging was achieved in 7 of the 10
patients treated.
Patients with compression fractures can be treated
with vertebro- or kyphoplasty followed by high-dose IGRT
treatment. Percutaneous cement augmentation is effective
treatment for pain, while it plays no role in local tumor control
and it is, thus, typically combined with postoperative radi-
ation. The pain relief afforded by these minimally invasive
procedures may greatly improve the patient’s tolerance to the
immobilization required for IGRT delivery. Gerszten et al. have
demonstrated the utility of high-dose irradiation following
percutaneous cement augmentation in a series of 26 patients
with a 92% local tumor control following single-fraction radio-
surgery (at a mean of 12 days after kyphoplasty) with a mean
dose of 18 Gy (range, 16–20 Gy prescribed to the 80% isodose
line).40
7.  Selection  of  candidates  for  high-dose
spinal  SBRT
Attempts to identify the best candidates for spinal SBRT
have been made. A prognostic index using recursive par-
titioning analysis has been proposed using data from 174
patients treated typically with a single fraction with a median
dose of 14 Gy (range, 8–24 Gy).41 Kaplan–Meier analysis was
performed to detect any correlation between survival and
histology. Histologies were divided into favorable (breast and
prostate), radioresistant (renal cell, melanoma and sarcoma),
and other (all other histologies). Association of the following
variables with overall survival: histology, gender, age, Karnof-
sky performance status (KPS), control of primary, extraosseous
metastases, time from primary diagnosis (TPD), dose (≤14 Gy
versus >14 Gy), extent of spine disease (epidural only, bone
and epidural, bone only), upfront or salvage treatment, pres-
ence of paraspinal extension, and previous surgery. Median
follow-up was 8.9 months. Median overall survival time from
SBRT was 10.7 months. Median overall survival intervals
for favorable histologies were 14 months, 11.2 months for
radioresistant histologies, and 7.3 months for other histolo-
gies (p = 0.02). Recursive partitioning analysis resulted in three
classes (p < 0.0001). Class 1 was defined as TPD of >30 months
and KPS of >70; Class 2 was TPD of >30 months and KPS of
≤70 or a TPD of ≤30 months and age <70 years old; Class 3
was TPD of ≤30 months and age ≥70 years old. Median OS
was 21.1 months for Class 1, 8.7 months for Class 2, and 2.4
months for Class 3. This index represents a simple and yet
effective approach to predict which patients may benefit most
from SBRT to spinal disease.
Chang et al. reported on the safety, effectiveness, and
patterns of failure obtained in a Phase I/II study of SBRT
for spinal metastatic tumors.42 A total of 74 lesions were
treated in 63 patients with near-simultaneous computed
tomography-guided SBRT. Spinal magnetic resonance imag-
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visit. No neuropathy or myelopathy was observed at a median
follow-up of 21.3 months (range 0.9–49.6 months). The actuar-
ial 1-year tumor progression-free incidence was 84% for all
tumors. Pattern-of-failure analysis showed that 47% of the
recurrences occurred in the epidural space adjacent to the
spinal cord, likely due in part to tumor underdosing in the
region due to spinal cord constraints which had been set to a
dose of 9–10 Gy. Although this value may be regarded as overly
conservative, especially in the radiation-naïve cases, this find-
ing is particularly useful in identifying cases that may be at
greater risk of local recurrence, e.g. lesions abutting ≤ 1 mm
from the thecal sac.
8.  Outlook  for  the  future
This review demonstrates that single dose SBRT is rapidly
gaining consensus as a method to treat metastatic tumor
to the spine as a single modality or in combination with
neurosurgical procedures.43 Remarkable consistency has been
demonstrated in reported outcomes with durable local control
rates in excess of 90% in large retrospective studies. While
the perspective of using single dose SBRT in spine metas-
tases is highly promising, the issue of tumor to cord proximity
and the associated risk of collateral cord damage continues
to represent a hurdle that hinders a wider application of this
technique. In particular, it is the need to apply ultra-high SBRT
doses that mandates meticulous and diligent use of labor-
intensive techniques to deliver treatment safely.
One resolution of this dilemma may result from a new
understanding of the biology of single dose radiotherapy.
When treated with standard fractionation, human tumors
exhibit a rank ordering of the dose required for 90% tumor
cure by their inherent tumor-type specific radiosensitivity.
This phenotypic feature of tumor radiobiology is not relevant
to tumor response to ultra-high radiation dose, as all tumor
types exhibit a near uniform response at the high range of
clinically feasible single dose SBRT. This phenomenon sug-
gests that high single dose SBRT might operate a mechanism
of tumor cell lethality that differs from that operating at low
dose exposures. In fact, such a mechanism has recently been
described as a co-dependent dual target radiation response,
with a threshold at a high radiation dose level, as such, it is
not functional at the traditional low dose/fraction mode.44,45
It has been shown that radiation exposure at the ultra-high
dose level engages a microvascular response that interferes
metabolically with tumor cell ability to properly repair radi-
ation damage, resulting in tumor cell death and tumor
cure. The understanding of this mechanism of action has
yielded new targets for selective tumor versus normal tissue
radiosensitization.46 Biological modifiers now used in exper-
imental tumor models enable up to a 6 Gy de-escalation of
the dose required for single dose tumor cure without affect-
ing normal tissue sensitivity.47 If such tumor-selective dose
reduction could convert 24 Gy tumor cure to a 15–18 Gy iso-
effect in clinical settings, it would significantly simplify the
treatment of spine tumors, as it will reduce or eliminate the
risk of collateral cord toxicity. It should, however, be empha-
sized that these approaches are still at an experimental phase
1
iotherapy 2 0 ( 2 0 1 5 ) 454–463
and must await further development before being introduced
into clinical practice.
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